

ΔVΔNOS

2021 CORPORATE CITIZENSHIP REPORT




TABLE OF CONTENTS

CEO LETTER	2
ABOUT AVANOS	3
ETHICS	4
Governance	
Compliance	
Political Spending and Lobbying	
Protecting Human Rights	
EMPLOYEES	6
Demographics	
Diversity, Equity and Inclusion	
Human Rights	
Employee Engagement	
Employee Wellness	
Employee Retention	
Compensation	
Occupational Health and Safety	
Training and Educational Opportunities	
SUPPLIERS	9
Corporate Social Compliance	
Conflict Minerals Reporting	
COMMUNITIES	10
Community Relations	
Charitable Giving	
PRODUCTS	11
Supply Chain	
Raw Materials	
Quality	
Packaging	
Unique Device Identification	
Electronic Instructions for Use	
ENVIRONMENTAL	14
Managing Waste	
Managing Greenhouse Gas Emissions	
Managing Water Use	

A MESSAGE FROM THE CEO

At Avanos, our commitment to operating ethically and in accordance with applicable global laws and regulations remains unwavering. While our priorities may occasionally shift to meet the needs of our customers and our business, our focus on being a good corporate citizen never changes.

That means no shortcuts – ever. We are, and always will be, committed to doing the right things for our employees, our customers, our shareholders and the communities in which we live and work.

We believe that being a good corporate citizen also means being accountable for our actions and responsibilities. To reflect this, we recently updated our guiding principles to include Accountability as a new corporate value.

We also established a formal Diversity, Equity & Inclusion Council to ensure that all Avanos employees feel valued, respected and heard. And, to continue on this journey, we modified our corporate mission statement to better represent our DE&I efforts: We deliver breakthrough medical device solutions to improve quality of life through a diverse and inclusive workforce.

We also proudly launched Women of Avanos Empowered – or WAVE – the first of a number of planned employee resource groups to meet the needs and interests of all our employees around the world.

The heart of our business remains getting patients back to the things that matter. For Avanos, that includes global efforts supporting COVID-19 patients and the medical professionals caring for them. As a co-sponsor of the 9th annual Atlanta Summit on Global Health, Avanos collaborated with other global health experts to identify strategies in “The Race to Beat COVID-19.”

It also means doing our part to help those in challenging situations. We were proud to make a \$50,000 donation to Direct Relief to assist people and communities in India hardest hit by COVID-19, as well as a donation of 5,000 of our closed-suction catheters for this effort. We also supported efforts to assist those affected by tornadoes throughout the midwestern United States with a \$10,000 donation to Direct Relief.

We’re pleased to share this report with you, and thank you for your interest in Avanos!



A handwritten signature in black ink that reads "Joseph F. Woody". The signature is fluid and cursive, written over a light grey background.

Joseph F. Woody
Chief Executive Officer
Avanos Medical

ABOUT AVANOS

This report covers the period of Jan. 1 through Dec. 31, 2021.

OVERVIEW

Avanos is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter. We are committed to creating the next generation of innovative healthcare solutions to address our most important healthcare needs, including reducing the use of opioids while helping patients move from surgery to recovery.

We develop, manufacture and market our recognized brands in more than 90 countries and hold leading market positions in multiple categories across our portfolio. With corporate headquarters in Alpharetta, Georgia, Avanos operates eight principal medical device production facilities, employing 4,500 people worldwide. 2021 net revenue was \$745 million.

Avanos Medical Inc. is traded on the New York Stock Exchange under the ticker symbol AVNS.

BUSINESS

Avanos is comprised of two franchises – Pain Management and Chronic Care. We offer therapies and solutions with a relentless focus on advancing change in the medical device industry to reduce the use of opioids while helping patients recover faster and improve their quality of life.

Avanos is vertically integrated and manufactures most of its products. Each franchise is supported by a dedicated sales force; a customer support team with significant industry experience and robust product training; and customer education programs. Avanos continues to invest in R&D to enhance the effectiveness, reliability and safety of our existing products, as well as to commercialize new products.

GOVERNANCE

Our culture is based on our commitment to operate ethically and in compliance with applicable global laws and regulations. Our governance for overseeing and managing our business includes:

- a board of directors that is 83% independent
- a clear reporting structure and lines of accountability
- a global code of conduct
- a comprehensive policy platform, including policies on human rights, labor, diversity and inclusion, and environmental issues
- oversight on key environmental, social and governance (ESG) issues

Board Diversity Overview	2021	% of Total as of December 2021
Independent members	5	83%
Women	2	33%
Ethnically diverse membership	1	17%
Total board members	6	

Avanos' board of directors provides oversight and guidance on all aspects of our businesses and relationships with stakeholders. Our annual proxy statement contains detailed information on our board and committee structure, the independence of the members, and the responsibilities and meeting frequency of the board and each committee. The board has established the following standing committees: audit, compensation, compliance, governance and executive. Each committee is responsible for reviewing policies on matters relevant to that committee.

Avanos has a robust compliance and ethics program, overseen by the board's Compliance Committee, the Management Compliance Oversight Committee, our Chief Ethics and Compliance Officer and our Senior Vice President of Global Quality Assurance and Regulatory Affairs. Key components of that program include: our quality and regulatory policies and procedures, which are designed to ensure compliance with applicable laws and regulations; and our anti-corruption policies and procedures, which are designed to ensure compliance with global anti-corruption standards, including the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act.

COMPLIANCE

The development, manufacturing, marketing, sale, promotion and distribution of Avanos products are subject to comprehensive government regulation. Government regulation by various national, regional, federal, state and local agencies, both in the United States and other countries, addresses (among other matters) inspection of, and controls over, research and laboratory procedures, clinical investigations, product approvals and manufacturing, labeling, packaging, marketing and promotion, pricing and reimbursement, sampling, distribution, quality control, post-market surveillance, record keeping, storage and disposal practices.

COMPLIANCE continued

Avanos operations are also affected by trade regulations in many countries that limit the import of raw materials and finished products, and bylaws and regulations that seek to prevent corruption and bribery in the marketplace (including the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, which regulate corporate interactions with government officials), as well as regulations that require safeguards for the protection of personal data. In addition, Avanos is subject to laws and regulations pertaining to healthcare fraud and abuse, including state and federal anti-kickback and false claims laws in the United States. The Physician Payment Sunshine Act, and comparable laws in other jurisdictions, also require Avanos and other manufacturers to annually report payments and items of value given to hospitals and doctors.

POLITICAL SPENDING AND LOBBYING

In 2021, Avanos engaged in federal lobbying activities in the United States in an effort to help alleviate the opioid crisis. We engaged the consulting firm ADVI to advise and represent the company on Medicare coverage and payment policy issues tied to the opioid issue before the Centers for Medicare and Medicaid Services (CMS). We engaged the law firm Polsinelli PC to advise us and lobby on our behalf before the US Congress and CMS to help ensure non-opioid alternatives like our pain management devices are appropriately accessible to patients and providers to avoid the use of opioids. Avanos is also a member of AdvaMed, a medical device industry association, which lobbies on behalf of its members.

Avanos does not currently operate a political action committee (PAC) in the United States or elsewhere. Similarly, the company makes no contributions to political candidates, PACs that contribute to candidates, or other organizations formed solely for the election or defeat of a public official in the United States or elsewhere.

PROTECTING HUMAN RIGHTS

We respect international social compliance and environmental principles aimed at promoting and protecting human rights and the environment. Avanos also promotes human rights in our supply chain through our Supplier Social Compliance Standards. The standards are designed to identify, prevent, mitigate and account for human rights violations, with a focus on countries at high risk for human rights abuses.

Our board of directors' Audit and Compliance Committees oversee our efforts to ensure compliance with the Avanos Code of Conduct, other internal policies and certain legal and regulatory requirements.

Compliance with the Avanos Code of Conduct and our Supplier Social Compliance Standards is also verified by an external auditor on an annual basis, in accordance with the United Kingdom Labor Standards Assurance System (LSAS). The LSAS framework is a review of the company's policies, procedures and practices used to identify labor standards abuses, mitigate risks, and drive improvement within the company and with certain external supply chain vendors. An external audit confirmed Avanos' compliance to the LSAS Level 3 requirements for 2021.

EMPLOYEES

DEMOGRAPHICS

Employees are our most-valued resource and are at the center of everything we do. Their talent, diversity and commitment are crucial to our innovation and success. Our work environment fosters personal, professional and corporate growth and nurtures innovation through product development and customer solutions. Our global teams work together in a spirit of cooperation to improve health and healthcare every day.

Global Employees	2021	% of Total
United States	962	21.1%
Latin America	3,365	73.9%
Europe, Middle East and Africa	110	2.4%
Asia-Pacific	118	2.6%
TOTAL	4,555	

Employee demographics represent the count as of Dec. 31, 2021

DIVERSITY, EQUITY AND INCLUSION

Avanos' commitment to diversity, equity and inclusion supports the company's goal of achieving success as we continue to grow our business and develop our workforce. Our commitment is also reflected in the important role that our Diversity, Equity & Inclusion ("DE&I") Council plays in our governance practices. Founded in 2021, the DE&I Council is comprised of employees from various salary levels, functional departments and geographic regions throughout Avanos.

Our DE&I Council plays a critical role in helping the company by:

- implementing Avanos' DE&I strategy and policies
- ensuring that DE&I is an integral part of the Avanos culture
- providing governance and oversight with respect to our DE&I endeavors
- advising senior leadership on Avanos' DE&I strategies to ensure they are in alignment with our overall business strategy
- recommending actions to implement, enhance and drive accountability for DE&I metrics

Ultimately, the Council aims to strengthen the engagement and motivation of our global workforce through the creation of a highly inclusive environment that allows a greater level of diversity at every level, thus driving better business outcomes. Our employee profile below reflects results on Dec. 31, 2021.

Employee Diversity	2021
Women – global director and above ¹	31.3%
Ethnic minorities – US director and above ¹	15.9%
Women – global salaried employees	42.9%
Ethnic minorities – US salaried employees	30.6%

¹Leaders in director-level position or higher

EMPLOYEES

HUMAN RIGHTS

The Avanos Human Rights in Employment Policy underscores our commitment to diversity and inclusion. The policy prohibits discrimination and harassment based on race, color, sex, pregnancy, sexual orientation, gender identity, age, religion, creed, national origin, disability, and other categories protected by applicable laws.

Avanos' commitment to protecting human rights is consistent with our respect for one another and our heritage of fairness, honesty and integrity. This commitment is formalized in our Human Rights in Employment Policy as well as the Avanos Code of Conduct. Our policies align with the goals of several international standards, including the International Labour Organization's Declaration on Fundamental Principles and Rights at Work and those of the UN Global Compact.

EMPLOYEE ENGAGEMENT

Avanos believes that employees who are engaged in their roles, treated as partners in the business and recognized for their efforts, are more satisfied and productive. Our goal is to ensure that each of our more than 4,500 employees understand how they contribute to the company's innovation and growth. We accomplish this through an employee recognition program and ongoing, two-way communications, including town halls, videos and podcasts, that allow employees to engage with and hear directly from Avanos leaders.

EMPLOYEE WELLNESS

Avanos takes its commitment to the ongoing health and safety of its employees seriously, offering far-reaching health and benefits packages including wellness and awareness programs. Wellness initiatives vary by location but include an Employee Assistance Program (EAP), health assessments, on-site exercise facilities, and employer-sponsored challenges that foster healthy habits.

EMPLOYEE RETENTION

In 2021, Avanos implemented a multi-tiered employee retention strategy, including:

- enhanced compensation and rewards, including expanded benefits and more flexible work arrangements
- fostering greater employee engagement through initiatives such as peer-to-peer coaching, internal promotions, a leadership development program and increased interactions with senior leaders
- recognizing employees for their efforts through a variety of awards, spotlights and appreciation events

COMPENSATION

Avanos compensates employees competitively and fairly in markets throughout the world. Compensation for salaried employees is strongly tied to performance objectives. Salaried employees above a certain pay grade have a substantial portion of their total compensation subject to performance objectives. More about our executive officer compensation can be found in our 2022 proxy statement.

OCCUPATIONAL HEALTH AND SAFETY

Avanos has undertaken a detailed plan for risk assessment and mitigation; upgrading safety management systems; issuing communications; and establishing a metric for safety initiatives based on leading metrics. Our operations leadership and management teams all have a safety component to their annual performance objectives and actively participate in the programs. Our safety goals involve creating total employee awareness, solid risk management and facility/equipment compliance, and high individual accountability for safety. We believe strongly in the recognition and celebration of outstanding achievements in safety.

2021 Health and Safety Highlights

4 of 8 locations recorded zero accidents and received the Crystal Eagle Award for excellence in safety performance

Equipment risk scores reduced 41% from previous year

Received over 4,000 employee engagement cards in our Avanos Observations Program – a self-reported performance program to improve employee safety, health and environmental processes

Supplements for production facility safety and environmental manuals have been incorporated into Avanos internal audit program

Robust safety protocols for COVID-19 included health screenings, infection prevention, contact tracing, PPE and sanitizing procedures

Employee Safety (Calendar Year)	2021
Fatalities	0.00
Permanently disabling injuries	0.00
Total reportable incident rate (TRIR)	0.21
North America	0.21
Europe	0.00
Middle East and Africa	0.00
Lost-time reportable incident rate (LTRIR)	0.16
North America	0.16
Europe	0.00
Middle East and Africa	0.00

TRAINING AND EDUCATIONAL OPPORTUNITIES

Because Avanos is a medical device manufacturer, employees are regularly trained in key areas required by the FDA and other applicable regulatory authorities, including topics such as documentation, safety, complaint handling, anti-bribery and quality, among others. In addition to regulated training, employees are educated on the Avanos Code of Conduct, so that all employees align with our cultural and behavioral expectations.

SUPPLIERS

CORPORATE SOCIAL COMPLIANCE

The Avanos Code of Conduct provides guidance for dealing with our customers, suppliers, employees, competitors and the public with integrity and in an ethical and appropriate manner.

We respect international social compliance and environmental principles aimed at promoting and protecting human rights and the environment. We integrate human rights into our direct and contracted operations, as well as through our supplier arrangements. Avanos policies align with the goals of several international standards, including the International Labour Organization's Declaration on Fundamental Principles and Rights at Work. These values are formalized in the Avanos Human Rights in Employment Policy and Instructions.

SUPPLIER SOCIAL COMPLIANCE STANDARDS

Social compliance is integral to Avanos' workplace accountability programs. These standards are driven by the belief that good corporate citizenship is essential to our long-term business success and must be reflected in our relationships and actions in our workplaces and the workplaces of those who are authorized to directly supply our business.

DUE DILIGENCE PROCESS

In selecting new, finished-product, contract manufacturing suppliers, Avanos uses a multi-level due diligence process that involves surveys, reviews of supplier policies, procedures, records and background/reference checks.

CALIFORNIA TRANSPARENCY IN SUPPLY CHAINS ACT DISCLOSURE

Avanos evaluates and addresses risks of human trafficking and slave labor throughout its supply chain. Verification of this process is completed by independent audits and/or self-assessments. During these audits, Avanos receives certification from certain of our direct suppliers that the materials incorporated into their products comply with the laws regarding slavery and human trafficking of the country in which they are doing business.

Avanos' Social Compliance Standards and Code of Conduct are enforced to help maintain internal and external social compliance accountability standards and procedures for suppliers, employees or contractors in regard to combating slavery and human trafficking.

CONFLICT MINERALS REPORTING

Conflict minerals are tungsten, tin, tantalum and gold, and any other mineral or its derivatives determined by the US Secretary of State to be financing conflict in the Democratic Republic of Congo (DRC) or any country that shares an internationally recognized border with the DRC.

Avanos conducts a reasonable country-of-origin inquiry (RCOI) to determine whether any materials used in our products originated in the DRC or an adjoining country or were from recycled or scrap sources. A summary of our RCOI, as well as the steps taken to exercise due diligence on the source and chain of custody of our product materials, is included in our Conflict Minerals Report, which can be found in our SEC filings.

COMMUNITIES

COMMUNITY RELATIONS

Avanos strives to improve the well-being of the people we touch through a range of health, humanitarian, economic and environmental initiatives to help sustain the communities where our employees work and live. We maintain strategic partnerships with organizations that address issues related to our business and that are of interest to our employees, customers and global communities.

CHARITABLE GIVING

Being a good corporate citizen includes giving to those in need, whether it's providing resources, offering financial support or donating time to help others.

Once again, employees across the United States participated in United Way campaigns that provided funding, resources, volunteers and other support targeted at advancing the common good. During its 2021 United Way fundraising campaign, Avanos employees contributed \$53,000, which the company matched with an additional 50 percent.

In 2021, as part of its continued response to the COVID-19 pandemic, Avanos co-sponsored the 9th annual Atlanta Summit on Global Health, hosted by the World Affairs Council of Atlanta in collaboration with CARE USA, the Center for Strategic and International Studies, and the Carter Center. The Summit – titled “The Race to Beat COVID-19” – convened diverse experts in global health policy and programs, including senior CDC leadership and policy expertise from Washington, DC and outside the United States.

In response to the catastrophic effects of the COVID-19 pandemic in India, Avanos donated \$50,000 to Direct Relief, a humanitarian aid organization active in more than 80 countries, to equip doctors and nurses with oxygen concentrators and other lifesaving medical resources. Avanos also donated 5,000 Avanos closed-suction systems to help people and communities hit hard by this crisis in India.

In December, when devastating tornadoes slammed communities across the Midwest and Southern regions of the United States, Avanos donated \$10,000 to Direct Relief to support disaster relief efforts and help with recovery.

While these were specific efforts in 2021, every year, Avanos' Matching Gifts program enables US employees to double their personal donations to qualified charitable organizations. Avanos matches all contributions to qualified organizations – such as not-for-profit entities and schools – over \$50 and up to \$1,000 per employee, per year.

PRODUCTS

SUPPLY CHAIN

Maintaining a responsible and resilient supply chain is a business imperative, and our relationships with suppliers are essential to our ability to deliver on promises to customers and other stakeholders. Avanos seeks to do business with suppliers who share our values of quality, service, fair dealing and our commitment to being a responsible corporate citizen.

The Supplier Social Compliance Standards (SSCS) are a vital pillar of Avanos' supply chain and align with our Code of Conduct and Human Rights in Employment Policy. These standards are driven by the belief that good corporate citizenship is essential to our long-term business success and must be reflected in our relationships and actions in Avanos workplaces and the workplaces of those who are authorized to directly supply our business. The practices reflect the values we uphold in our own policies, and we expect our suppliers to follow these standards and requirements.

RAW MATERIALS

Avanos uses a wide variety of raw materials and other inputs in our production processes. We base our purchasing decisions on quality assurance, cost-effectiveness and regulatory requirements. We work closely with our suppliers to ensure continuity of supply while maintaining high quality and reliability. We primarily purchase these materials from external suppliers, some of which are single-source suppliers.

Global commodity prices can affect pricing of certain raw materials we use. The prices of resins and finishing supplies often fluctuate in response to changes in oil prices. Prices of these commodities can be volatile and have varied significantly in recent years, contributing to fluctuations in our operating results. More information can be found in our SEC filings.

Avanos relies on product materials and inputs, such as polyethylene and other commodities, in the manufacture of polymer products that are developed and sold globally.

Materials Used (metric ton)	2021
Polymers	1,675

PRODUCTS

QUALITY

Ensuring quality is an essential part of Avanos' business strategy, and a culture of quality is the foundation for meeting the expectations of healthcare providers and their patients. It is our policy to design, manufacture, deliver and service products that meet or exceed customer expectations for quality, performance and value. We accomplish this by:

- establishing quality objectives, processes, procedures and practices that meet or exceed customer and regulatory requirements
- establishing accountability for quality systems management
- providing resources necessary to execute the quality management system
- conducting regular assessments of quality systems and practices to promote continuous process, product and service improvement, and to ensure compliance with applicable laws and regulations

External regulations and industry best practices, as well as internally developed standards, define our quality criteria. Programs are established to measure compliance with these and report results to senior management. These quality standards and established quality system processes drive the continuous improvement activities that ensure that Avanos products are safe and effective for customers.

Should they become necessary, product field action/recall programs are in place to promptly address potential product or safety issues. These processes are tested periodically to ensure that they are effective and efficient.

In 2021, the following voluntary field actions/recalls were conducted by Avanos:

Product	Regions
JTP pH Indicator Strips pH 0-6.0	UK
ambIT* Pump Over-Infusion	Australia
BALLARD* Liberator	Canada
NeoMed* Legacy Syringe	Singapore, Australia
Digestive Health products: MIC* PEG feed connector MIC* G-Tube MIC* G Bolus MIC* Jejunal and CORFLO* NI One Pain products: ON-Q* System with Soaker ON-Q* System with Dual Silver Soakers	Austria, Belgium, Chile, Czech Republic, Finland, France, Germany, Greece, Ireland, Israel, Italy, Luxembourg, Netherlands, Romania, Saudi Arabia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, United Kingdom, United Arab Emirates
BALLARD* MAP Catheter	France, Italy, Denmark, Switzerland, Netherlands, Greece, Germany, United Kingdom, United States
MIC* Bolus Gastrostomy Feeding Tube - 20 Fr	Japan
MIC* Percutaneous Endoscopic Gastrostomy PEG Kit - 20 Fr - PULL	USA, Canada, Chile
MIC* Percutaneous Endoscopic Gastrostomy PEG Kit with ENFit® Connectors - 20 Fr - PULL	

Avanos maintains an ongoing commitment to protecting customer health and safety. Our product-safety scientists are trained and accredited in the fields of toxicology, biocompatibility testing and health-risk assessments. Most have doctoral degrees and several are board-certified by the American Board of Toxicology. Safety assessments conducted by our product-safety experts cover the complete life cycle of a product: research and development, manufacture, sale, use and disposal.

PRODUCTS

PACKAGING

Our product packaging helps ensure the quality and safe delivery of our products to customers around the world every day. As we focus on continuous improvement, we incorporate sustainable packaging considerations early in the design process, balancing environmental concerns with the need to protect product quality and transport products efficiently and economically. Optimizing packaging designs for patient safety and customer ease of use, while meeting sterilization and supply chain needs, are also key considerations.

UNIQUE DEVICE IDENTIFICATION

Avanos employs Unique Device Identification (UDI)-compliant labeling.

The UDI system is used to mark and identify medical devices through their distribution and use. This helps reduce medical errors and more quickly identify medical devices in the case of adverse events or recalls, in addition to providing an accessible source of definitive device identification information. Scanning bar codes containing standardized product information not only streamlines recall management and facilitates device data tracking by clinical research registries, but also offers hospitals the opportunity to better manage inventory and integrate standardized product information into their electronic medical records.

Using UDI to document the device(s) in a patient's record improves the accuracy of surveillance and patient care, and furthers our mission to be the best at getting patients back to the things that matter.

ELECTRONIC INSTRUCTIONS FOR USE

Avanos transitioned all US-based customers from printed paper instructions to Electronic Instructions for Use (eIFU) as another way to reduce our carbon footprint.

With the product, customers can scan a QR code to access a full set of usage instructions through a dedicated website instead of receiving paper packaging inserts. eIFUs provide real-time updates for customers and eliminate the need to store paper instructions when storage space within hospitals and other clinical settings is often minimal.

Paper production, distribution and disposal require a large amount of energy and raw materials. Using eIFUs will eliminate over 275 tons of paper consumption annually, as well as oil, water and energy associated with production, distribution and disposal of paper.

eIFU Sustainability Benefits Contribute to:

Reducing oil consumption by more than 100,000 GALLONS	Reducing water consumption by more than 2,600,000 GALLONS	Reducing energy consumption by over 1,100,000 KILOWATTS
--	--	--

ENVIRONMENTAL

Striving for clean air, clean water and a healthy environment is fundamental to the way we manufacture our products. As in previous years, we continue to rigorously track and report metrics related to waste, utilities and regulatory activity in all owned facilities and buildings within our scope of responsibility.

MANAGING WASTE

In 2021, Avanos has worked diligently to be 80% landfill-free of total waste. However, our goal is to recycle all of our manufacturing waste and eliminate landfill use. This is a goal that Avanos has been purposefully pursuing and will continue to set as a priority.

Because managing waste is important to our stakeholders, and because the majority of our products are single use, we have made waste management a key priority.

Nonhazardous Waste (MT)	2021
Percentage of Nonhazardous Waste Diverted from Landfill	-78.3%
Total Nonhazardous Waste Generated	2,039.6
Landfilled	441.6
Incineration w/o Heat Recovery	188.4
Waste-to-Energy	1.4
Recycled	1,372.9
Re-used	34.6
Beneficial Use	0.8
Direct Land Application	0.0

Hazardous Waste (kg)	2021
Percent Hazardous Waste Diverted from Landfill	-100%
Total Hazardous Waste Generated	166,638.0
Landfilled	0.0
Biological Treatment	0.0
Blended Fuel	87,097.7
Chemical Treatment	20,357.4
Deep-Well Injection	0.0
Incineration w/o Heat Recovery	32,585.9
Permanent Storage	14,792.9
Recycled	5,537.0
Surface Impoundment	0.0
Thermal Treatment	6,267.0

ENVIRONMENTAL

MANAGING GREENHOUSE GAS EMISSIONS

Our measurements track Scope 1 (direct) emissions, which includes on-site fuel generation. We also track and report Scope 2 (indirect) emissions, which include electricity, steam and other energy generated off-site and purchased by Avanos.

Energy Efficiency (million Btu)	2021
Total electricity purchased	86,393.03
Total electricity generated*	599.44
Total fuel oil	66.66
Recycled	0.00
Other natural gas	3,288.17
Total biofuel purchased	0.00
Total steam generated	0.00
Total energy purchased	89,747.86
Percent of biofuel purchased	0.00

*Renewable energy is generated at our Tijuana plant. In 2021, our Tijuana facility generated 5.7% of its electricity from its Photovoltaic system.

Greenhouse Gas Emissions (CO ₂ e)	2021
Scope 1 (direct)	229.24
Scope 2 (indirect)	11,466.53
Total emissions (tCO ₂ e)	11,695.77

MANAGING WATER USE

Although water is not utilized in many Avanos processes, water use is measured and recorded for manufacturing and all general business operations, tracking it to its discharge destination. Where we use process water at our facilities, effluent water is returned in accordance with all applicable guidelines.

Manufacturing Water Use [m ³]	2021
Influent	67,376
Surface water	0
Municipal water	52,886
Ground water	14,490
Effluent	43,538
Surface water discharge	0
Municipal water discharge	43,538